Skip to content
lifestyle.latabloid.com/
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Belite Bio, Inc
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
August 12, 2026
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
August 11, 2026
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
August 6, 2026
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit
May 20, 2026
Belite Bio to Participate in Four Upcoming Investor Conferences
May 19, 2026
Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease
April 21, 2026
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
March 31, 2026
Belite Bio to Participate in the Leerink Global Healthcare Conference
March 2, 2026
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
March 2, 2026
Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results
February 23, 2026